| Symbol | KLRA |
|---|---|
| Name | KAILERA THERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 180 THIRD AVENUE, WALTHAM, MA 02451 |
| Telephone | 508-440-9475 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002096997 |
| Description | None |
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Read moreRenaud Ronald C JR 🟡 adjusted position in 0 shares (1 derivative) of Kailera Therapeutics, Inc. (KLRA) at $5.25 Transaction Date: Jun 09, 2026 | Filing ID: 267493
Read moreHengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Read more(30% Negative) KAILERA THERAPEUTICS, INC. (KLRA) Reports Q2 2026 Financial Results
Read moreKailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
Read moreHengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions
Read more(99% Neutral) KAILERA THERAPEUTICS, INC. (KLRA) Announces Business Combination
Read moreKailera Therapeutics, Inc. - Common stock (KLRA) was added to the exchange traded list on NASDAQ
Read more